Showing 3961-3970 of 4063 results for "".
- Gene Therapy Luxturna Approved in EU to Restore Vision in People With Rare Inherited Retinal Diseasehttps://modernod.com/news/gene-therapy-luxturna-approved-in-eu-to-restore-vision-in-people-with-rare-inherited-retinal-disease/2479651/Novartis announced that the European Commission (EC) approved Luxturna, a one-time gene therapy for the treatment of patients with vision loss due to a genetic mutation in both copies of the RPE65 gene and who have enough viable retinal cells. The authorization is valid in all 28 member st
- U.S. Appeals Court Rules Against Allergan Over Validity of Restasis Patentshttps://modernod.com/news/u-s-appeals-court-rules-against-allergan-over-validity-of-restasis-patents/2479660/Allergan’s patents on its blockbuster eye drug Restasis are invalid, a U.S. appeals court ruled, according to a Bloomberg report. Without issuing a formal opinion, the U.
- Envision Research Institute Announces Search for Post Doctoral Fellows to Study Low Visionhttps://modernod.com/news/envision-research-institute-announces-search-for-post-doctoral-fellows-to-study-low-vision/2479664/The Gigi & Carl Allen Envision Research Institute (ERI) is now calling for letters of intent to apply for its next round of postdoctoral research fellowships. Launched in 2015 with a goal to restore function to those who are blind and visually impaired, the ERI provides access to funds, facil
- American Academy of Optometry Announces Barbara Caffery, OD, PhD, FAAO, as Presidenthttps://modernod.com/news/american-academy-of-optometry-names-barbara-caffery-od-phd-faao-as-president/2479665/The American Academy of Optometry has named Barbara Caffery, OD, PhD, FAAO, the incoming President of the American Academy of Optometry. Dr. Caffery was formally inducted during the Academy’s annual meeting in San Antonio, Texas on November 10, 2018. She is the first Canadian woman to serve as pr
- Acucela Initiates Phase 3 Study of Emixustat Addressing Patients with Stargardt Diseasehttps://modernod.com/news/acucela-initiates-phase-3-study-of-emixustat-addressing-patients-with-stargardt-disease/2479674/Acucela announced that on November 7, 2018, the first patient has enrolled in a study to evaluate Acucela’s leading drug candidate, emixustat hydrochloride (emixustat), in subjects with macular atrophy secondary to Stargardt disease. The study is a multicenter, randomized, double-masked, a
- Takeda, Shire Shareholders to Vote on Merger Deal Next Monthhttps://modernod.com/news/takeda-shire-shareholders-to-vote-on-merger-deal-next-month/2479678/Takeda and Shire announced that shareholders will vote on December 5 on the companies’ proposed $62-billion merger, with the Japanese drugmaker targeting January 8, 2019 for closing of the deal. Takeda CEO Christophe Weber remarked “with the date of our extraordinary general meeting (
- Two Studies Measure Performance of Acuvue Oasys with Transitions Light Intelligent Technology Contact Lenseshttps://modernod.com/news/two-studies-measure-performance-of-acuvue-oasys-with-transitions-light-intelligent-technology-contact-lenses/2479693/Johnson & Johnson Vision announced that data from two new studies on the visual effects of photochromic contact lenses were presented at the 2018 American Academy of Optometry Annual Meeting in San Antonio. These are the first scientific presentations focused on photochromic contact lens tech
- New Data from Johnson & Johnson Vision Highlights the Need and Potential Standards for Evidence-Based Decision-Making in Myopiahttps://modernod.com/news/new-data-from-johnson-johnson-vision-highlights-the-need-and-potential-standards-for-evidence-based-decision-making-in-myopia/2479698/Johnson & Johnson Vision announced that Noel A Brennan, PhD, the company’s Global Platform Lead for Myopia Control, will present data on myopia progression and investigational methods to control it at the 2018 American Academy of Optometry Annual Meeting, held November 7-10 in San Antonio, Te
- Unum Finds Significant Number of Millennials Value Vision Insurancehttps://modernod.com/news/unum-finds-significant-number-of-millennials-value-vision-insurance/2479704/Employee benefits provider Unum finds the elimination of vision benefits could motivate more than a third (34 percent) of U.S. workers ages 25 to 34 to look for a new job. These results and other key findings were part of an online poll among 1,227 working U.S. adults conducted by Unum in July.</
- ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticalshttps://modernod.com/news/proqr-in-licenses-worldwide-rights-to-ophthalmology-drug-candidate-from-ionis-pharmaceuticals/2479723/ProQR Therapeutics announced the signing of an agreement with Ionis Pharmaceuticals to license QR-1123 (formerly IONIS-RHO-2.5Rx), an RNA medicine for autosomal dominant retinitis pigmentosa (adRP) caused by the P23H mutation in the rhodopsin (RHO) gene. “Building on th